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A series of pyrrolizidine esters, amides and ureas were prepared and tested for 5-HT4
and 5-HT3 receptor binding, 5-HT4 receptor agonism in the rat tunica muscularis mucosae
(TMM) assay, and for 5-HT3 receptor-mediated functional antagonism in the BezoldJarisch reflex assay. Several pyrrolizidine derivatives were identified with high affinity
for the 5-HT4 receptor including benzamide 12a (SC-53116), a potent and selective 5HT4 partial agonist that exhibits efficacy in promoting antral contractions and activity in
promoting gastric emptying in canine models. Also discovered were 5-HT4 receptor
antagonists, including imidazopyridine amide 12h (SC-53606), which is a potent and
selective 5-HT4 receptor antagonist with a pA2 value of 8.13 in the rat TMM assay. NMethyl indole ester 13d was identified as a potent 5-HT4 antagonist with a pA2 value of
8.93. High selectivity was observed for these pyrrolizidine derivatives versus other
monoamine receptors including 5-HT1, 5-HT2, D1, D2, α1, α2 and β receptors.

Introduction
Serotonin (5-hydroxytryptamine, 5-HT) functions as both a hormone and a
neurotransmitter, controlling a host of central and peripheral effects in mammalian
systems, and is noteworthy in its diversity of receptors and subtypes.1 Given the diversity
and ubiquitous nature of serotonin receptors, it is imperative to prepare potent and
selective 5-HT ligands to enable pharmacological studies of the various receptor subtypes
and to serve as drugs to treat diseases that have an etiology in serotonin receptor
imbalance.
The 5-HT4 receptor was discovered by Baxter, Craig and Clarke2 and by Dumuis and
Bockaert3 in the gut and brain, respectively, and is expressed in a wide variety of tissues
including brain, heart, bladder, gut and kidney4,5 Initial demonstration that the
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gastrointestinal prokinetic6 benzamides cisapride 1 and renzapride 2 enhance contractile
activity at neuronal 5-HT4 receptors in the guinea pig ileum was made by Craig and
Clarke.7 It was later demonstrated by Dumuis and Bockaert that 5-HT4 receptors mediate
the relaxation of smooth muscle of the inner muscularis mucosae of rat esophagus8 and
also the cholinergic stimulation of the ascending colon of the guinea pig.9 New tools
including fluorescent antagonists have recently been developed for the study of 5-HT4
receptors,10 and an excellent review of the 5-HT4 receptor and key ligands was recently
published.11
Selective ligands for the 5-HT4 receptor show promise in the treatment of a wide
variety of diseases including the irritable bowel syndrome (IBS) and other gastrointestinal
motility disorders, urinary incontinence, atrial arrhythmia11,12 and cognitive disorders.13
Gastrointestinal motility disorders are a collection of syndromes which are characterized
by a hypofunctional bowel, abnormal motility patterns and transit, and painful gut wall
distension. The mechanisms thought to be common to many of these motility disorders is
the malfunction of enteric nervous system control of peristalsis at the level of the
myenteric plexus.14 Compound 1 had been marketed for motility disorders15 but was
withdrawn due to QT prolongation.16,17 The 5-HT4 partial agonist tegaserod (compound
3, SDZ HTF 919) was approved in 2002 for the treatment of constipation-predominant
irritable bowel syndrome (IBS).18-20 Tegaserod shows a clear effect on the total colonic
transit time in healthy subjects, and a significant improvement in patients with
constipation-predominant IBS in a phase III trial.21 Compound 4, Prucalopride,22
accelerates colonic transit in healthy subjects but without modification of either gastric
emptying or small bowel transit.23 In patients with severe constipation, the benzamide
prucalopride elicited a dose-dependent effect on acceleration of the overall transit time.24
3

We have pursued the exploration of various conformationally-constrained bicyclic and
tricyclic amines as ligands for the serotonin 5-HT4 receptor to treat gastrointestinal
motility disorders. Our focus has been on receptor selectivity to avoid potential side
effects, and we were particularly cognizant of avoiding the dopamine D2 receptor, as D2
antagonism is responsible for extrapyramidal side effects and hyperprolactinaemia
observed with the marketed benzamide metoclopramide.25 We were also vigilant of other
monoamine receptors, including the 5-HT2 receptor, which is potently inhibited by
compound 1.26 We were attracted to the pyrrolizidine azabicyclo[3.3.0]octane ring
system and reasoned that this fairly rigid bicyclic amine could provide a fruitful scaffold
for preparing potent and selective serotonin 5-HT4 agonists. A similar approach was used
by King in the discovery of renzapride (2), which was designed to mimic the higher
energy conformers of azabicyclic quinolizidine benzamides of their earlier studies,27 and
in particular was designed to lock in the cis form of the ring junction of the azabicycle
and reduce the steric bulk extending outward around the basic nitrogen. The Beecham
group then also employed a pyrrolizidine scaffold.28, 29 More recently, the 5-HT4 receptor
agonist meso-pyrrolizidine 5 (SK-951) has been described which is a potent
gastrointestinal prokinetic agent in rats and dogs.30, 31 Our own successful approach
employing the pyrrolizidine moiety led to the potent 5-HT4 receptor partial agonist 12a32
by attaching the pyrrolizidine to the traditional aromatic moiety of prokinetic benzamides
1 and 2. In addition, we explored the attachment of other aromatic amides to the
pyrrolizidine bicyclic amine, seeking to mimic the intramolecular H-bond of the 2methoxybenzamides. This approach led to the potent 5-HT4 receptor antagonist 12h.33
We also explored both amides and esters of the pyrrolizidine amine moiety with indole
and indazole aromatic moieties, inspired by the potent 5-HT3 receptor antagonists
4

tropisetron34 and granisetron,34, 35 particularly considering that tropisetron was shown to
be the first surmountable antagonist of 5-HT4 receptors3 and Buchheit demonstrated that
the ester derivative of metoclopramide, SDZ 205-557, is a potent antagonist of 5-HT4
receptors.36
We were aware of the toxicity of the pyrrolizidine alkaloid natural products37 and
considered the fact that toxicity among pyrrolizidine alkaloids varies dramatically with
differences in chemical structure. Certain pyrrolizidine natural products can form highly
reactive pyrrole intermediates upon metabolism by CYP3A4 which are responsible for
their nascent toxicity. A ring nucleus containing a double bond at the 1,2-position is
considered to be essential for toxic effects of the alkaloid, along with additional hydroxyl
groups around the nucleus. Based on this premise of structure-specificity we decided to
explore the pyrrolizidine nucleus for incorporation into novel 5-HT4 receptor agonists and
antagonists. This paper details our work employing the pyrrolizidine scaffold resulting in
the potent 5-HT4 receptor agonist 12a, as well as 5-HT4 receptor antagonist 12h, and
other potent 5-HT4 antagonists.

Chemistry
The (S,S)-carbinol (-)-trachelanthamidine 9 was prepared by a diastereoselective
alkylation of the chiral tin enolate of 3-(4-chlorobutyryl)-4-(S)-isopropyl-1,3-thiazolidine2-thione 7 with 5-acetoxy-2-pyrrolidinone as elegantly described by Yoshimitsu Nagao38
and summarized in Scheme 1. We analyzed the Mosher ester of 9 by 19F NMR to confirm
the enantiomeric purity which showed the material to be ≥ 99.1% e.e.
Aminomethylpyrrolizidine 11 was prepared by Mistunobu reaction of 9 with phthalimide
in the presence of triphenylphosphine and diethylazodicarboxylate to afford phthalimide
5

derivative 10, and the phthalimide moiety was removed with hydrazine to afford 11
(Scheme 2). Coupling of the amine with an aryl carboxylic acid was then typically
accomplished with 1,1’-carbonyl diimidazole (CDI) to give the requisite pyrrolizidine
amides 12. Esters of 9 were prepared by treating the imidazolide derived from the
appropriate aryl carboxylic acid and CDI with the sodium salt of alcohol 9 to afford esters
13 (Scheme 3). The enantiomer of aminomethylpyrrolizidine 11 and its derivatives (in
particular, benzamide ent-12a, the enantiomer of 12a, were prepared from the (R)enantiomer of thiazolidinethione 7.
Benzimidazolone 15a and oxindole urea 15b were prepared by treatment of the sodium
salt of the corresponding benzimidazolone 14a or oxindole 14b with phosgene followed
by the aminomethylpyrrolizidine 11 (Scheme 4). Imidazol[1,2-a]pyridine-8-carboxylic
acid 17 was prepared by reacting 2-aminonicotinic acid 16 with chloroacetaldehyde, and
6-chloroimidazo[1,2-a]pyridine-8-carboxylic acid 19 was prepared from methyl 2-amino5-chloronicotinate 18 with chloroacetaldehyde followed by saponification (Scheme 5).
Similarly, 6-chloroimidazo[1,2-a]pyridine-3-methyl-8-carboxylic acid 21 was prepared by
alkylative esterification of 2-aminonicotinic acid 16, and regioselective chlorination with
t-butyl hypochlorite to afford 20, followed by conversion to the imidazopyridine with 2bromopropionaldehyde and hydrolysis of the ester to afford carboxylic acid 21 (Scheme
6). The pyrrolizidine esters and amides of these imidazopyridines were prepared by the
general methods described in Schemes 2 and 3.

6

Results and Discussion
Initial testing of pyrrolizidine 5-HT4 receptor ligands was accomplished using the rat
esophageal tunica muscularis mucosal (TMM) tissue2, 39 as this model allows for
determination of full cumulative dose response curves to agonists. Serotonin 5-HT4
receptor antagonists were also evaluated using the TMM model. Binding to serotonin 5HT4 receptors in guinea pig striatum was measured utilizing [3H]-GR113,808 as the
ligand. Binding to serotonin 5-HT3 receptors in rat cortical tissue was measured using
[3H]-GR656630. Functional 5-HT3 antagonism was measured utilizing the von BezoldJarisch reflex model.40
Pyrrolizidine 5-HT4 agonists are summarized in Table 1. In the rat TMM assay, the
chiral pyrrolizidine benzamide 12a and its distomer ent-12a had EC50 values of 16.5 ±
3.8 nM and 323 ± 46 nM, respectively. A plot of the TMM activity of 12a and ent-12a
relative to serotonin is shown in Figure 2 demonstrating that the pyrrolizidine benzamide
12a has comparable potency to serotonin (16.5 nM vs. 9.0 nM for 5-HT) and has 80% of
the efficacy of serotonin in this preparation. The distomer ent-12a is 36 times less
potent than serotonin. The potency of 12a relative to its enantiomer is reflected in 5-HT4
receptor binding. Pyrrolizidine 12a has a Ki value of 5.2 nM, while ent-12a inhibits
ligand binding by only 18% at 500 nM (Table 1). Benzamide 12a is approximately 30X
more potent in binding to the 5-HT4 receptor relative to its 5-HT3 binding (Ki = 152 nM).
In contrast to the 30X difference in 5-HT4 binding, 12a is only half as potent as ent-12a
in 5-HT3 binding. We previously reported a similar trend with compound 6 and its
enantiomer, where the 5-HT4 receptor showed a greater discernment of the antipodes than
the 5-HT3 receptor, although in that case the eutomer was the same compound for both
receptors.41 Functional antagonism of the 5-HT3 receptor is demonstrated by inhibition
7

of the von Bezold-Jarisch reflex in mice for both 12a and ent-12a (87% at 10 mpk for
both compounds).
The ethoxy benzamide 12b was prepared in an attempt to increase 5-HT3 potency,
which was successful in boosting 5-HT3 receptor binding by 6-fold (Ki = 25 nM),
however, the compound was approximately 12X less potent in the rat 5-HT4 TMM assay,
so 5-HT3 receptor binding potency was boosted at the expense of 5-HT4 potency. The
methiodide quaternary ammonium salt 12c was prepared to probe the possibility of
synthesizing a potent radiolabeled pyrrolizidine analog employing radiolabeled methyl
iodide. The quaternary ammonium salt 12c was indeed very potent in binding to the 5HT4 receptor (Ki = 0.35 nM), but despite its greater potency in binding, 12c was
markedly less potent than 12a as an agonist in the TMM functional assay, presumably due
to membrane transport limitations of the quaternary salt. Compound 13a is the ester
corresponding to 12a and was the most potent compound tested in our hands for both 5HT4 receptor binding (Ki = 183 pM) and in functional agonism at the 5-HT4 receptor in
the TMM assay (EC50 = 1.5 nM). It is actually a partial agonist at the 5-HT4 receptor,
with 57% efficacy as an agonist relative to serotonin. N-isopropyl benzimidazolone urea
15a, which incorporates the benzimidazolone moiety of BIMU 842 and DAU 621543
exhibited potent binding at the 5-HT4 receptor (Ki = 7.0 nM) but was 22X less potent in
5-HT4 agonism than 12a.
The excellent potency of the pyrrolizidine moiety in 5-HT4 receptor agonism prompted
us to consider employing this scaffold for the preparation of antagonists, indeed we were
encouraged in this regard by the potent but partial agonism of benzoate ester 13a.
Agonism of the 5-HT4 receptor may be dependent upon a planar array of the amide bond
with the aromatic ring system, enabled by an intramolecular H-bond between the amide
8

NH and the methoxy group as for 12a, or between the amide NH and the
benzimidazolone carbonyl of 15a. The 5-HT4 agonist efficacy of ester 13a is lower
(57%) apparently due to the inability to form this H-bond and the corresponding
conformational mobility.
Table 2 includes pyrrolizidine amides and ureas that are functional 5-HT4 antagonists in
the rat TMM assay employing different aromatic groups. All of these compounds were
determined to have EC50 values for agonism in the rat TMM assay of >10,000 nM. Two
of the derivatives tested were determined to be inactive in the rat TMM antagonism assay
at concentrations of up to 100-1000 nM including indole carboxamide 12d, and
indolizine 12e, which borrows the indolizine moiety described by Bermudez.44 We
employed an imidazopyridine aromatic nucleus with the nitrogen lone pair orthogonal to
the aromatic pi-system (compounds 12f-i), pointing toward the amide NH in an attempt to
mimic the intramolecular hydrogen bond present in the 2-methoxybenzamide prokinetic
5-HT4 agonists. Additionally, we were intrigued that the bridgehead nitrogen lone pair is
partially delocalized into the amide carbonyl as in the 4-aminobenzamides 1 and 2,
making the carbonyl oxygen more electron rich and favoring coplanarity of the aromatic
heterocycle and the amide. The structural similarity to benzofuran amides 4 and 5 is also
apparent. Nonetheless we found that these compounds function as 5-HT4 receptor
antagonists. Several imidazopyridines afforded good 5-HT4 antagonist activity, including
3-ethylimidazopyridine 12f (pA2 = 6.56). The role of the second nitrogen atom in
antagonist imidazopyridine 12f relative to inactive indolizine 12e is noteworthy. The 6chloro substituent was incorporated in analog 12h to boost binding based on structural
overlays done with the benzamide moiety of the prokinetic benzamides, assuming a
similar binding mode for the two series based on modeling considerations. Unsubstituted
9

imidazopyridine 12g was moderately potent (pA2 = 6.75), whereas addition of the
chlorine in the 6-position boosted potency of compound 12h33 by over an order of
magnitude (pA2 = 8.13). Imidazopyridine 12h exhibited very potent binding to the 5-HT4
receptor (Ki = 1.4 nM). Incorporation of a 3-methyl substitutent was probed in order to
augment potency with an additional hydrophobic interaction from the synthetically
accessible imidazopyridine, but further substitution with the 3-methyl group decreased
the 5-HT4 inhibitory potency of compound 12i (pA2 = 7.09) relative to 12h. Oxindole
urea 15b, which is structurally related to benzimidazolone 5-HT4 receptor agonist 15a, is
an antagonist that exhibits a pA2 value of 7.0. As with the imidazopyridines, we
originally hoped that the oxindole carbonyl could participate in an intramolecular
hydrogen bond with the urea NH. Oxindole 15b exhibits potent binding to the 5-HT4
receptor (Ki = 6.8 nM).
Pyrrolizidine ester 5-HT4 receptor antagonists are included in Table 3. The esters were
inspired by the work of Buchheit who reported SDZ 205-557, the ester analog of
metoclopramide, as the first potent antagonist of 5-HT4 receptors.36 These compounds all
lack agonist activity in the TMM assay (EC50 >10,000 nM). Based on the inhibitory
potency of 6-chloroimidazopyridine amide 12h we prepared the corresponding ester 13b
which is a moderate 5-HT4 receptor antagonist (pA2 = 6.75). Next, we prepared esters
incorporating the indole and indazole aromatic moieties present in tropisetron and
granisetron, respectively. Attempted attachment at the indole 2-position afforded Nmethyl indole-2-carboxylic ester 13c which was inactive, but good antagonism was
obtained with 3-substituted indoles and indazoles, particularly with N-methyl indole-3carboxylic ester 13d, which exhibited exceptional potency as an antagonist. 5Methoxyindole-3-carboxylate ester 13e exhibited moderate inhibitory potency at the 510

HT4 receptor (pA2 = 7.15), and potency was markedly increased for the 5-fluoro
derivative 13f in 5-HT4 inhibitory potency (pA2 = 8.5) as well as binding to the 5-HT4
and 5-HT3 receptors (Ki = 700 pM and 10 nM, resp.). Indazole ester 13g had good
inhibitory potency (pA2 = 8.48) and the corresponding N-methyl indazole derivative 13h
had comparable potency (pA2 = 8.56). These indazoles exhibited potent subnanomolar
binding to the 5-HT4 receptor (Ki = 800 pM and 400 pM, respectively), and moderate
binding to the 5-HT3 receptor (Ki = 135 nM and 20 nM, respectively). The N-methyl
analog was thus modestly more potent than the N-H analog toward both receptors. Both
indazoles were free of binding at 5-HT1, 5-HT2, D1, D2, α1, α2, β1, and β2 receptors.
Thus, the most potent member of the pyrrolizidine ester 5-HT4 receptor antagonist series
summarized in Table 3 is N-methyl indole-3-carboxylic ester 13d with a pA2 value of
8.93, which is comparable in potency to the Glaxo antagonist GR-113808 (pA2 = 9.39).
Indole 13d is a very potent dual receptor 5-HT4/5-HT3 ligand, with a Ki = 183 pM at the
5-HT4 receptor and Ki = 5.0 nM at the 5-HT3 receptor. This pyrrolizidine ester is free of
binding at 5-HT1, 5-HT2, D1, D2, α1, α2, β1, and β2 receptors (Ki > 10 uM).
In general, the esters are more potent as 5-HT4 antagonists than the corresponding
amides, although the present work only allows for two direct comparators. Specifically,
N-methyl indole ester 13d is more potent than the N-methyl indole carboxamide 12d. In
contrast, the 6-chloroimidazopyridine amide 12h is more potent than the corresponding
ester 13b.
In vivo 5-HT4 agonism was examined in conscious dogs by recording contractile
activity of the distal region of the stomach (antrum), as well as along other portions of the
gastrointestinal tract. Test compounds were intravenously administered to fasted animals

11

during Phase I (a period of quiescence that lasts about 50-80 minutes) of the
interdigestive migrating motor complex (MMC). The maximal contractile activity that
occurred during Phase III of the MMC was used to normalize the motility response to the
compound. Pyrrolizidine amide 12a stimulated sustained antral and jejunal contractile
activity as well as a brief augmentation of ileal and colonic contractions (Figure 3).
The antral responses to intravenous dosing of 12a, ent-12a and compound 1 in the
canine contractility model are plotted in Figure 4. Pyrrolizidine benzamide 12a exhibited
an ED50 of 0.010 mg/kg iv, whereas benzamide 1 was 5-fold less potent with an ED50 of
0.056 mg/kg iv. Distomer ent-12a was approximately 45X less potent than 12a in
promoting gastric antral contractions with an ED50 of 0.45 mg/kg iv. A maximally
effective dose of pyrrolizidine 12a induced antral contractions which were approximately
60% of the maximum Phase 3 contractions, compared to 54% for compound 1, and 69%
for compound 2 (not shown).
In-vivo gastrointestinal prokinetic efficacy was also determined in a functional model
for gastroparesis employing gamma scintigraphy. Since 5-HT4 agonists enhance solid
gastric emptying largely by increasing the force of contraction of the gastric antrum, the
canine antral contractile response was used to select compounds for the gastroparesis
model. In the gastroparesis model, an alpha-adrenergic agonist (2-methyl-3-[(2E)pyrrolidin-2-ylideneamino]phenol) inhibits food-induced gastric antral and duodenal
contractions, thus mimicking motor abnormalities characteristic of clinical
dysmotilities.45 Enhancement of gastric emptying in the gastroparesis model is
demonstrated by pyrrolizidines 12a, ent-12a and benzamide 1 (Figure 5). Pyrrolizidine
benzamide 12a was shown to be approximately 30X more potent than benzamide 1 in
enhancing gastric emptying (ED50 = 0.001 mg/kg vs. an ED50 = 0.03 mg/kg for compound
12

1. As expected, distomer ent-12a was less potent than both benzamide 1 and
pyrrolizidine 12a, with an ED50 of 1.0 mg/kg.
5-HT4 agonism data is summarized in Table 4 along with canine antral contractility and
canine solid gastric emptying for the pyrrolizidine benzamides 12a, ent-12a, and the
benzamide 1. Pyrrolizidine 12a is the most potent compound in vitro, as well as in vivo
in both canine models motility models. Benzamide 1 has an ED50 of 55 nM in the rat
TMM assay, whereas benzamide 2 exhibits an ED50 of 98 nM. Compound 2 is also more
potent than benzamide 1 in the antral contractility model, with an ED50 of 0.015 mg/kg iv.
Pyrrolizidine derivatives of the present series are highly selective for the 5-HT4
receptor. Pyrrolizidine 12a is very potent as a partial agonist at the 5-HT4 receptor and in
binding to the 5-HT4 receptor (Ki = 5.2 nM). Compound 12a exhibits moderate binding
at the 5-HT3 receptor (Ki = 152 nM), but no detectible binding (Ki > 10,000 nM) at any
of the other monoamine receptors tested (5-HT1, 5-HT2, D1, D2, α1, α2, and β receptors).
Imidazopyridine 12h, as reported previously, 33 is a very potent antagonist at the 5-HT4
receptor (Ki = 1.4 nM; pA2 = 8.13) with excellent selectivity versus the other monoamine
receptors tested (Ki > 10 µM). Standards included for comparison are compound 6,
which we have reported to be a potent and selective dual 5-HT4 agonist and 5-HT3
receptor antagonist, and compound 1, which shows potent inhibition of α1 receptors (Ki =
30 nM) and 5-HT2 receptors (6.1 nM).
In summary, incorporation of the pyrrolizidine scaffold has resulted in the discovery of
potent and selective ligands for the 5-HT4 receptor, including the potent and selective 5HT4 agonist 12a, with excellent efficacy in canine antral motility and gastric emptying
models. Toxicological profiling of 12a revealed that the compound is active in the Ames
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assay after S9 activation, so the compound was not pursued as a clinical candidate. It is
interesting to note that metabolic activation giving rise to mutagenicity appears to be
enantiospecific, as the enantiomer ent-12a is not mutagenic with or without S9
activation. The potency and efficacy of this series has prompted analog work to avoid
metabolic activation by bridgehead-methyl substitution.46 It is worth noting in this
context that pyrrolizidine 5 is substituted at the bridgehead carbon, which would not
permit the formation of a pyrrole-containing metabolite. Nevertheless, pyrrolizidine 12a
represents a useful pharmacological tool.47-50 Work employing the pyrrolizidine scaffold
also resulted in the discovery of imidazopyridine 12h, which is a potent and selective 5HT4 receptor antagonist33 as well as the potent N-methylindole 5-HT4 receptor antagonist
13d. Related work in these labs on conformationally-constrained amines also led to the
discovery of azanoradamantane 6 which is a potent, non-mutagenic and selective dual 5HT4 agonist/5-HT3 antagonist.41,51,52

Experimental Section
(-)-Trachelanthamidine (9). The (S,S)-carbinol (-)-trachelanthamidine 9 was prepared
by a diastereoselective alkylation of the chiral tin enolate of 3-(4-chlorobutyryl)-4-(S)isopropyl-1,3-thiazolidine-2-thione 7 with 5-acetoxy-2-pyrrolidinone and subsequent
reduction with lithium aluminum hydride as described by Yoshimitsu Nagao38 to afford 9
(3.12 g, 45.5%) as a colorless oil: [α]D = +9.2 (c = 0.195 g/dL in CHCl3; 10 cm); [α]365 =
-63.1 (c = 0.195 g/dL in CHCl3; 10 cm). The Mosher ester was prepared by treatment of
the alcohol with the Mosher acid chloride [from (S)-(-)-α-methoxy-α(trifluoromethyl)phenylacetic acid and thionyl chloride] and pyridine. 19F NMR analysis
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of the peak at -172.17 ppm and the absence of the peak at -172.29 ppm from the
diastereomeric standard showed that the material was ≥ 99.6% diastereomeric purity, or
≥99.1% e.e.
2-[(1S,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethyl]-1H-isoindole-1,3(2H)-dione
(10). To a solution of alcohol 3 (1.44 g, 10.2 mmol) in dry THF (45 mL) was added
triphenylphosphine (5.35 g, 20.4 mmol) and phthalimide (3.00 g, 20.4 mmol). The
solution was then cooled to 0°C and diethylazodicarboxylate (3.21 mL, 3.55 g, 10.4
mmol) was added dropwise over 15 minutes. The reaction was then stirred for 1 h at 0°C
and then 16 h at rt. Concentration gave a residue which was purified on silica gel eluting
with MeOH (saturated with NH3)/CHCl3 (4/96, then 6/94) to afford the desired
phthalimide 10 (2.12 g, 82%) as a pale yellow crystalline solid: mp 72-73°C; IR (MIR)
1763, 1706.5 cm-1. [α]D = -2.5°; [α]365 = -13.3° (c = 0.285 g/dL in chloroform). 1H
NMR (300 MHz, CDCl3) δ 7.86 (2H, m), 7.73 (2H, m), 3.76 (2H, d, J = 7.1 Hz), 3.28
(1H, m), 3.21 (1H, m), 2.94 (1H, dt, J = 10.2, 5.9 Hz), 2.51 (2H, m), 2.12 (1H, m), 1.99
(1H, m), 1.90-1.63 (3H, m), 1.43 (1H, m).
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C NMR (75 MHz, CDCl3) δ 167.8, 133.5,

131.5, 122.7, 67.7, 54.6, 53.9, 44.9, 40.3, 31.6, 31.0, 25.8. Anal calcd for
C16H18N2O2:0.4H2O C 69.24; H, 6.83; N, 10.09. Found C, 69.12; H, 6.56; N, 9.94.
HRMS calcd for C16H18N2O2 270.1369, found 270.1369.
(1S,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethylamine dihydrochloride (11). To a
solution of phthalimide 10 (4.11 g, 15.2 mmol) in ethanol (60 mL) was added hydrazine
hydrate (3.70 g, 74 mmol) and the reaction was stirred for 15 h at rt. The resulting
suspension was concentrated to give a residue. To the residue was added 4 N KOH (50
mL, presaturated with NaCl) and the mixture was extracted with chloroform (15 X 20

15

mL). The combined extracts were dried over sodium sulfate and concentrated to give the
title amine 11 (2.13 g, 100%) as a yellow semisolid, which may be stored under argon at 30°, if necessary, before use in the subsequent step. 1H NMR (300 MHz, CDCl3) δ 3.13
(2H, m), 2.95 (1H, m), 2.74 (2H, m), 2.56 (2H, m), 2.03 (1H, m), 1.98-1.63 (4H, m), 1.62
– 1.43 (2H, m). Dihydrochloride salt of 11: 1H NMR (300 MHz, d4-MeOD) δ 3.97 (1H,
m), 3.79 (1H, m), 3.46 (1H, m), 3.29-3.03 (3H, m), 2.51–2.34 (2H, m), 2.32 – 1.78 (5H,
m).
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C NMR (75 MHz, d4-MeOD) δ 70.4, 54.4, 53.9, 42.5, 40.7, 29.8, 29.4, 24.3.

HRMS MH+ calcd for C8H16N3 141.1392, found 141.1394.
4-Amino-5-chloro-N-[(1S-cis-hexahydro-1H-pyrrolizin-1-yl)methyl]-2methoxybenzenecarboxamide, hydrochloride (12a, SC-53116). To a solution of 4acetamido-5-chloro-2-methoxy-benzoic acid (3.70 g, 15.2 mmol) in DMF (15 mL, freshly
distilled under high vacuum) was added 1,1'-carbonyldiimidazole (2.46 g, 15.2 mmol)
which resulted in a vigorous gas evolution. After 40 min at rt a solution of the free base
amine 11 (2.13 g, 15.2 mmol) in DMF (6 mL) was added and reaction was stirred for 40 h
at rt. Concentration gave a yellow oil which was treated with 15% K2CO3 (65 mL) and
extracted with chloroform (4X). The combined organic extracts were washed
successively with water (2X) and brine and dried over sodium sulfate to give a pale
yellow solid (5.9 g). Purification on silica gel (170 g) eluting with MeOH (saturated with
NH3)/CHCl3 (15/85) gave 4-(acetylamino)-N-[(7aS)-hexahydro-1H-pyrrolizin-1ylmethyl]-5-chloro-2-methoxybenzamide (4.89 g, 88%) as a colorless solid after drying
for 1 h at 100°C: mp 131-132°C; [α]D = -8.8° (c = 1.2 g/dL); IR (MIR) 3407, 3310, 1696,
1656 cm-1. 1H NMR (300 MHz, CDCl3) δ 8.33 (1H, br s), 8.16 (1H, s), 8.12 (1H, s), 7.98
(1H, t, J = 5 Hz), 3.95 (3H, s), 3.47 (2H, br s), 3.19 (2H, m), 2.94 (1H, m), 2.56 (2H, m),

16

2.28 (3H, s), 2.19 – 1.47 (7H, m).
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C NMR (75 MHz, CDCl3) δ 168.5, 163.2, 155.9,

135.0, 131.3, 117.0, 114.2, 104.2, 68.0, 55.8, 54.3, 53.9, 45.2, 42.4, 31.3, 31.2, 25.5, 24.2.
Anal calcd for C18H24N3O3Cl C 59.09, H, 6.61, N, 11.48, Cl, 9.69. Found C, 58.76; H,
6.68; N, 11.42; N, 10.02. HRMS calcd for C18H24N3O3Cl 365.1506, found 365.1514.
A solution of the acetamide (4.88 g, 13.3 mmol) in ethanol (670 mL) was treated with
potassium hydroxide (4.49 g, 80 mmol) and heated under reflux for 2 h. Concentration
gave a residue to which was added water (150 mL) and the resulting mixture was
extracted with chloroform (4X). the combined organic extracts were washed successively
with water (2X) and brine and dried over sodium sulfate. Concentration gave the desired
benzamide as a solid (4.21 g, 98%) which was purified on silica gel eluting with MeOH
(saturated with NH3)/CHCl3 (12/88, then 16/84) to afford the pure free base of 12a (3.86
g, 90%) as a colorless solid: mp 165.5-166.5°C. [α]D = -10.6°; [α]365 = -36.7° (c = 0.330
g/dL in chloroform). 1H NMR (300 MHz, CDCl3) δ 8.11 (1H, s), 7.80 (1H, t, J = 6 Hz),
6.30 (1H, s), 4.40 (2H, s), 3.90 (3H, s), 3.47 (2H, m), 3.19 (2H, m), 2.98 (1H, m), 2.57
(2h, m), 2.10 – 1.47 (8H, m).
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C NMR (75 MHz, CDCl3) δ 164.5, 157.3, 146.9, 132.7,

111.8, 111.2, 97.6, 68.5, 55.9, 54.8, 54.3, 45.7, 42.7, 31.7, 31.6, 25.9. Analysis
calculated for C16H22N3O2Cl: C, 59.34; H, 5.85; N, 12.98; Cl, 10.95. Found C, 59.09; H,
6.71; N, 12.84; Cl, 11.18.
To a suspension of the free base of 12a (3.52 g, 10.87 mmol) in methanol (10 mL) was
added a solution of HCl (10.87 mmol) in methanol [prepared by the addition of acetyl
chloride (0.76 g, 10.9 mmol) to methanol (10 mL)]. The resulting solution was
concentrated to give a solid which was redissolved in methanol (5 mL) and added slowly
to diethyl ether (3 liters) with rapid stirring. The resulting suspension was stored at 0°C
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for 16 h. Filtration gave the desired hydrochloride salt of 12a (3.63 g, 88%) as a colorless
solid: mp 103-105°C. IR (MIR) 3323, 3194, 1620, 1594 cm-1. 1H NMR (300 MHz, d4MeOD) δ 7.79 (1H, s), 6.52 (1H, s), 3.98 (1H, m), 3.93 (3H, s), 3.76 (1H, ddd, J = 3.0,
7.2, 10.8 Hz), 3.53 (2H, d, J = 6.3 Hz), 3.20 (1H, m), 3.10 (1H, td, J = 11.4, 6.0 Hz), 2.39
(1H, m), 2.30 – 1.79 (6H, m).
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C NMR (75 MHz, d4-MeOD) δ 167.7, 159.6, 133.2,

111.5, 111.2, 98.5, 72.3, 56.6, 55.8, 55.5, 46.5, 31.2, 31.1, 25.8. HRMS calcd for
C16H22N3O2Cl 323.1415, found 323,1400. Analysis calculated for
C16H22N3O2Cl:HCl:0.75H2O: C, 51.41; H, 6.61; N, 11.24; Cl, 18.97. Found C, 51.58; H,
6.70; N, 10.94; Cl, 18.57. [α]D = -2.6°; [α]365 = -6.4° (c = 0.47g/dL in methanol).
Amide Coupling General Procedure. We have found that benzamide couplings
utilizing 4-amino-5-chloro-2-methoxy-benzoic acid generally proceed very well without
acetamide protection of the 4-amino group. According to this general procedure, to a
solution of carboxylic acid (1 equivalent) in DMF (freshly opened) is added 1,1'carbonyldiimidazole (1 equivalent) which results in a vigorous gas evolution. After 0.5 to
1 h at rt a solution of the amine 11 in DMF is added and reaction is stirred for 2 h at rt
followed by 2 h at 50°C. Concentration affords a residue which is treated with 15%
K2CO3 and extracted with chloroform (3X). The combined organic extracts are washed
successively with water (2X) and brine and dried over sodium sulfate. Concentration
affords the desired product which may be purified by crystallization or may be pure
enough to carry on directly to the hydrochloride salt formation as described above for
12a. Alternatively, purification on silica gel eluting with MeOH (saturated with
NH3)/CHCl3 (15/85) affords the pure coupled material as the free base which is then
converted to the hydrochloride salt.
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4-Amino-5-chloro-N-[(1R,7aR)-hexahydro-1H-pyrrolizin-1-ylmethyl]-2methoxybenzamide (ent-12a, SC-53117). This compound was prepared from (+)trachelanthamidine, prepared according to the method of Nagao38 and continued as above
for the enantiomeric series beginning with 3-(4-chlorobutyryl)-4-(R)-isopropyl-1,3thiazolidine-2-thione to afford ent-12a: Analysis calculated for
C16H22N3O2Cl:1.2HCl:0.8H2O: C, 50.31; H, 6.54; N, 11.00; Cl, 20.42. Found C, 50.45;
H, 6.62; N, 10.67; Cl, 20.40. [α]D = +0.5°; [α]365 = +3.3° (c = 0.183 g/dL in methanol).
4-Amino-5-chloro-2-ethoxy-N-[(1S,7aS)-hexahydro-1H-pyrrolizin-1ylmethyl]benzamide hydrochloride (12b). To a solution of 4-amino-5-chloro-2methoxy-benzoic acid (1 eq) in DMF was added 1,1'-carbonyldiimidazole (1 eq). After 1
h at rt a solution of the amine 5 in DMF was added. After the reaction was complete,
aqueous workup as for 12a and chromatography on silica gel afforded the requisite amide
12b: 1H NMR (400 MHz, d4-MeOD) δ 7.77 (1H, s), 6.49 (1H, s), 4.17 (2H, q, J= 7 Hz),
3.96 to 3.91 (1H, m), 3.78 to 3.73 (1H, m), 3.54 to 3.52 (2H, m), 3.47 to 3.41 (1H, m),
3.24 to3.17 (2H, m), 3.13 to 3.06 (1H, m), 2.43 to 2.34 (1H, m), 2.29 to 2.21 (1H, m),
2.19 to 2.09 (2H, m), 2.07 to 1.99 (1H, m), 1.96 to 1.89 (1H, m), 1.86 to 1.79 (1H, m),
1.48 (3H, t). Analysis calculated for C17H24N3O2Cl:HCl:0.5H2O: C, 53.27; H, 6.84; N, ;
Cl, 18.50. Found C, 53.14; H, 6.88; N, 10.87; Cl, 20.07.
(1S,7aS)-1-{[(4-Amino-5-chloro-2-methoxybenzoyl)amino]methyl}-4methylhexahydro-1H-pyrrolizinium iodide (12c). To a solution of the free base of 12a
(32.5 mg, 0.10 mmol) in toluene (5 mL) was added a solution of MeI (12.5 uL, 0.103
mmol) in toluene (50 mL). The reaction flask was wrapped with foil and allowed to
stand at rt for 24 h. Filtration afforded the methiodide salt 12c (35 mg, 75%) as a pale
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yellow solid: 1H NMR (300 MHz, d4-MeOD) δ 7.79 (1H, s), 6.53 (1H, s), 3.95 (3H, s),
3.88 (1H, dd, J = 8.1, 3.4 Hz), 3.78 – 3.63 (3H, m), 3.63 – 3.56 (2H, m), 3.45 (1H, m),
3.23 (3H, s), 2.52 (1H, m), 2.40 – 2.13 (4H, m), 2.12 – 1.90 (2H, m).
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C NMR (75

MHz, d4-MeOD) δ 167.7, 159.5, 150.5, 133.1, 111.4, 111.1, 98.5, 83.8, 67.2, 66.3, 56.7,
53.5, 47.7, 41.8, 31.3, 29.3, 25.1. Anal calcd for C17H25N3O2I: C, 47.45; H, 5.86; N,
9.77. Found C, 47.17; H, 5.92; N, 9.54.
N-[(1S,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethyl]-1-methyl-1H-indole-3carboxamide (12d). To a solution of N-methylindole-3-carboxylic acid (1.0 eq) in DMF
at rt was added CDI (1 eq). After 1 h a solution of amine 11 (1 eq) in DMF was added
and the solution stirred for 16 h at rt. Aqueous workup and chromatography on silica gel
afforded the desired indole carboxamide 12d: C18 H23 N3 O Anal calcd for C18H23N3O:
C, 72.70; H, 7.80; N, 14.13. Found C, 72.91; H, 7.68; N, 13.92.
N-exo(Tetrahydro-1H-pyrrolizin-4(5H)-ylmethyl)-3-ethylindolizine-1carboxamide (12e). 3-Ethylindolizine-1-carboxylic acid44 (190 mg, 1.0 mmol) was
suspended in CHCl3 (2 mL). Oxalyl chloride (184 uL, 2.1 mmol) and DMF (1 drop) were
added and the mixture stirred for 2 h. The reaction mixture was concentrated in vacuo,
azeotroping once with toluene. To the residue dissolved in CHC13 was added a solution
of exo-tetrahydro-1H-pyrrolizin-4(5H)-methylamine 11 (140 mg, 1.0 mmol), and
triethylamine (279 uL, 2.0 mmol) in CHCl3 (2 mL) and the mixture was stirred for 18 h.
The organic solution was washed with 1N NaOH, brine, dried over K2CO3, filtered and
concentrated to give a crude oil. Purification on silica gel eluting with MeOH (saturated
with NH3)/CHCl3 (30/70) gave the desired compound 12e as a very hydroscopic solid
(190 mg, 63%). 1H NMR (400 MHz, d4-MeOD) δ 8.20 (1H, d, J= 18 Hz), 8.02 (1H, t, J=
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14 Hz), 7.03 to 6.97 (3H, m), 6.80 to 6.75 (1H, m), 4.06 to 3.99 (1H, m), 3.83 to 3.75
(1H, m), 3.67 (2H, d, J= 6 Hz), 3.46 to 3.42 (1H, m), 3.25 to 3.18 (1H, m), 3.18 to 3.03
(1H, m), 2.54 to 2.45 (1H, m), 2.37 to 2.29 (1H, m), 2.22 to 2.12 (2H, m), 2.09 to to1.86
(3H, m). Anal calcd for C19H25N3O:2.0 H2O: C, 65.68; H, 7.25; N, 12.09. Found C,
65.79; H, 7.56; N, 12.03. MS calcd for C19H25N3O: 311.43, Found: 311.19. Attempts to
make the HCl salt resulted in a brown oil, so the compound was tested as the free base.
N-exo(tetrahydro-lH-pyrrolizin-4(5H)-ylmethyl)-3-ethylimidazo[1,2-a]pyridine-lcarboxamide monohydrochloride (12f). 3-Ethylimidazo[1,5-a]pyridine-l-carboxylic
acid44 (190 mg, 1.0 mmol) was suspended in CHCl3 (2 mL). Oxalyl chloride (184 uL, 2.1
mmol) and DMF (1 drop) were added and mixture stirred for 2 h. The reaction mixture
was concentrated in vacuo, azeotroping once with toluene. To the residue dissolved in
CHCl3 was added a solution of exo-tetrahydro-lH-pyrrolizin-4(5H)-methylamine 11 (140
mg, 1.0 mmol) and triethyl amine (279 uL, 2.0 mmol) in CHCl3 (2 mL) and the mixture
stirred for 18 h. The organic solution was washed with 1N NaOH, brine, dried over
K2CO3, filtered and concentrated to give a crude oil which was chromatographed on silica
gel eluting with 5% CH3OH(NH3)/CHCl3 to give 110 mg (35%) of desired compound as
the free base. The HCl salt 12f was prepared in the same manner as for 12a: Anal calcd
for C18H24N4O.HCl:0.75H2O C, 57.91; H, 7.24; N, 15.01; Cl, 12.35. Found C, 58.15; H,
6.95; N, 14.95; Cl, 12.25. MS calcd for C18H24N4O 312, found 312.
N-exo((4-s,7α
α-s)-Tetrahydro-1H-pyrrolizin-4(5H)-yl)imidazo[1,2-a]pyridine-8carboxamide (12g). Imidazol[1,2-a]pyridine-8-carboxylic acid monohydrochloride 17
(198 mg, 1.00 mmol) and 1,1’-carbonyldiimidizole (178 mg, 1.1 mmol) were dissolved in
DMF (5 mL) and stirred for 1 h. A solution of the aminomethylpyrrolizidine 11 (120 mg,
0.85 mmol) in Et3N (560 µl, 4.0 mmol) was added to the reaction mixture and stirred for
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1 h before concentrating. The residue was partitioned between CHCl3 and 5% aqueous
K2CO3. The organic layer was dried over Na2SO4 and concentrated. The residue was
purified by preparative thin-layer chromatography eluting with 20/80 MeOH/CHCl3
containing 0.25% NH4OH. The filtrate was concentrated and the residue was dissolved in
CHCl3 and filtered through celite and concentrated to yield the imidazopyridine amide
(144 mg, 43%) as an oil. This residue was converted to the pyrrolizidine hydrochloride
salt 12g using a mixture of acetyl chloride/MeOH: IR: 1579, 1659, 1697, 3049 and 3325
cm-1. Anal calcd for C16H20N4O.2.0H2O:2.2 HCl:0.25 CHCl3 C: 46.12; H: 6.25; N:
13.24. Found: C: 46.22; H: 6.41; N: 13.43.
N-exo((4-S,7α
α-s)-Tetrahydro-1H-pyrrolizin-4(5H)-yl)-6-chloroimidazo[1,2a]pyridine-8-carboxamide dihydrochloride (12h, SC-53606). 6-Chloroimidazo[1,2a]pyridine-8-carboxylic acid monohydrochloride 19 (1.39 g; 6.0 mmol) and 1,1’carbonyldiimidizole (972 mg, 6.0 mmol) were dissolved in DMF (10 mL) and stirred for
1 h. A solution of aminomethylpyrrolizidine 11 (800 mg, 5.7 mmol) in Et3N (2.5 mL)
was added to the reaction mixture and stirred for 1 h before concentrating. The residue
was partitioned between CHCl3 and 5% aqueous K2CO3. The organic layer was dried
over Na2SO4 and concentrated. The residue was purified by preparative thin-layer
chromatography eluting with 20/80 MeOH/CHCl3 with 0.25% NH4OH. The filtrate was
concentrated and the residue was dissolved in CHCl3 and filtered through celite and
concentrated to yield the amide (1.42 g) as an oil. This residue was converted to the HCl
salt using a mixture of acetyl chloride/MeOH to afford 12h: IR: 1652cm-1. 1H NMR
(400 MHz, d4-MeOD) δ 8.83 (1H, d, J= 2 Hz), 7.99 (1H, d, J= 2 Hz), 7.96 (1H, d, J= 1.3
Hz), 7.70 (1H, 1.3 Hz), 4.05 to 3.98 (1H, m), 3.82 to 3.75 (1H, m), 3.689 (2H, d, J= 6
Hz), 3.49 to 3.42 (1H, m), 3.25 to 3.18 (1H, m), 3.16 to 3.08 (1H, m), 2.54 to 2.45 (1H,
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m), 2.37 to 2.29 (1H, m), 2.22 to 2.12 (2H, m), 2.09 to1.86 (3H, m). Anal calcd for
C16H19ClN4O.H2O.HCl C: 51.48; H: 5.94; N: 15.01; Cl: 19.00. Found: C: 51.32; H:
5.64; N: 14.88; Cl: 18.86.
N-exo((4-s,7α
α-s)-Tetrahydro-1H-pyrrolizin-4(5H)-yl)-6-chloroimidazo[1,2a]pyridine-3-methyl-8-carboxamide (12i). A suspension of 2-aminonicotinic acid 16
(5.0 g; 0.036 mol) and K2CO3 (5.0 g; 0.36 mol) in DMF (50 mL) were heated to reflux,
and then the solution was cooled to ambient temperature. Iodomethane (5.1 g, 2.2 mL,
0.036 mol) was then added to the mixture and the solution was stirred for 18 h. The
mixture was filtered and concentrated. The residue was filtered through a pad of silica,
eluting with 5/95 EtOH/CH2Cl2 containing 0.1% NH4OH. The resulting solution was
concentrated and the residue was suspended in Et2O, filtered and concentrated to yield
methyl 2-aminonicotinate (3.2 g).
The methyl 2-aminonicotinate (800 mg, 0.00525 mol) was dissolved in MeOH (15
mL). HCl gas was passed over the solution until the solution was acidic (pH 2), then the
solution was concentrated. The residue was dissolved in MeOH (15 mL) and tbutylhypochlorite (570 mg, 5.25 mmol) was added to the reaction mixture and stirred
until the yellow color dissipated. Additional t-butyl hypochlorite was added until tlc (5/95
EtOH/CH2Cl2 containing 0.1% NH4OH) indicated that the starting material was
consumed. The reaction mixture was concentrated and the residue was partitioned
between CH2Cl2 and 5% aqueous NaHCO3. The organic layer was washed with 5%
aqueous sodium thiosulfate, dried over MgSO4 and concentrated. The solid residue was
suspended in 1:1 CH2Cl2/hexane, filtered, washed with hexane, and suction dried to yield
methyl 2-amino-5-chloronicotinate 20 (250 mg, 26%): mp 139-40°C. Anal calcd for
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C7H7ClN2O2 C: 45.60; H: 3.78; N: 15.01; Cl: 19.00. Found: C: 44.72; H: 3.75; N: 15.00;
Cl: 19.20.
Methyl 2-amino-5-chloronicotinate 20 (7.0 g, 0.045 mol) and 2-bromopropionaldehyde
(15.8 g, 0.116 mol) were combined in EtOH (100 mL) and refluxed until tlc (5/95
EtOH/toluene containing 0.1% NH4OH) indicated that the starting material was
consumed. The reaction mixture was concentrated and the residue was triturated with
acetone, then partitioned between CH2Cl2 and 5% aqueous K2CO3. The organic layer was
dried over MgSO4 and concentrated. The residue was triturated with Et2O to yield methyl
6-chloroimidazo[1,2-a]pyridine-3-methyl-8-carboxylate (5.0 g, 50%) as a solid: IR: 1720
cm-1. Anal calcd for C10H9ClN2O2 C: 53.47; H: 4.04; N: 12.47; Cl: 15.78. Found: C:
53.14; H: 4.06; N: 12.37; Cl: 16.03. MS MH+ calcd for C10H9ClN2O2 225, found 225.
The methyl 6-chloroimidazo[1,2-a]pyridine-3-methyl-8-carboxylate (5.0 g; 0.022 mol)
was suspended in 6N HCl (50 mL) and heated to reflux for 2 h. The reaction mixture was
concentrated to near dryness. The residue was suspended in acetone and the solid filtered
and washed with acetone to yield 6-chloroimidazo[1,2-a]pyridine-3-methyl-8-carboxylic
acid 21 (4.9 g) as the HCl salt: IR: 1704 and 3175 cm-1. Anal calcd for C9H7ClN2O2.HCl
C: 43.75; H: 3.26; N: 11.34; Cl: 28.70. Found: C: 43.54; H: 3.16; N: 11.26; Cl: 28.74.
MS MH+ calcd for C9H7ClN2O2 211, found 211.
To a solution of 6-chloroimidazo[1,2-a]pyridine-3-methyl-8-carboxylic acid 21 (247
mg, 1.00 mmol) in DMF (5 mL) was added 1,1’-carbonyldiimidizole (178 mg, 0.011
mol) and the solution stirred for 1 h. Aminomethylpyrrolizidine 11 (120 mg, 0.85 mmol)
and Et3N (560 µL, 4.0 mmol) were added to the reaction mixture and the solution was
stirred for 1 h before concentrating. The residue was partitioned between CHCl3 and 5%
aqueous K2CO3. The organic layer was dried over Na2SO4 and concentrated. The residue
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was purified by preparative thin-layer chromatography eluting with 20/80 MeOH/CHCl3
containing 0.25% NH4OH. The filtrate was concentrated and the residue was dissolved in
CHCl3 and filtered through celite and concentrated to yield an oil (144 mg, 43%). This
residue was converted to the HCl salt the desired imidazopyridine amide 12i using a
mixture of acetyl chloride/MeOH. 1H NMR (400 MHz, d4-MeOD) δ 9.10 (1H, d, J= 2.5
Hz), 8.56 (1H, d, J= 2.5 Hz), 7.89 (1H, d, J=1 Hz), 4.08 to 4.03 (1H, m), 3.81 to 3.75
(1H, m), 3.63 (2H, d, J= 6 Hz), 3.51 to 3.45 (1H, m), 3.22 to 3.19 (1H, m), 3.16 to 3.09
(1H, m), 2.68 (3H, d, J= 1 Hz), 2.52 to 2.46 (1H, m), 2.35 to 2.27 (1H, m), 2.25 to 2.14
(2H, m), 2.09 to 2.03 (1H, m), 1.99 to 1.87 (2H, m). Anal calcd for C7H8N2O2 C: 55.26;
H: 5.30; N: 18.41. Found: C: 54.90; H: 5.36; N: 18.26. Anal calcd for C19H26N4O2:1.25
H2O:2.2 HCl:0.25 MeOH C: 46.55; H: 6.18; N: 12.41; Cl: 25.12. Found: C: 46.87; H:
5.94; N: 12.47; Cl: 25.34.
(1R,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethyl 4-amino-5-chloro-2methoxybenzoate hydrochloride (13a). To NaH solid (52 mg of 60% dispersion,
washed with hexane, 31 mg NaH) was added a solution of alcohol 9 (185 mg, 1.31 mmol)
in DMF (2 mL) at 0°C. After the effervescence was complete (0.5 h) this sodium
alcoholate was added to the imidazolide of 4-amino-5-chloro-2-methoxybenzoic acid
[330 mg, 1.31 mmol at 0°C. [The imidazolide was prepared by the addition of CDI (656
mg, 4.05 mmol) to 4-amino-5-chloro-2-methoxybenzoic acid (800 mg, 3.97 mmol).
Aqueous workup and recrystallization from ether/CHCl3 afforded the requisite
imidazolide (780 mg, 78%) as colorless crystals, mp 122-122.5°C.] The reaction was
allowed to warm to rt over 2 h. Water was added and the mixture extracted with CHCl3.
The combined organic extracts were washed with water (2X) and brine and dried over
Na2SO4. Concentration gave a solid (362 mg) which was purified by chromatography on
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silica gel eluting with i-PrOH(NH3)/CHCl3 to afford the free base ester (129 mg, 30%).
To a solution of the free base (117 mg, 0.36 mmol) in MeOH (1.5 mL) was added
HCl/MeOH [prepared by the addition of acetyl chloride (23 uL, 25 mg, 0.36 mmol) to
MeOH (1.5 mL) to afford the desired monohydrochloride salt of ester 13a (98 mg, 72%)
as a beige solid: mp 191-193°C. HRMS calcd for C16H21N2O3Cl 325.1319, found
325.1298. Anal calcd for C16H21N2O3Cl:HCl:0.25H2O C, 52.54; H, 6.20; N, 7.66; Cl,
19.39. Found C, 52.44; H, 6.06; N, 7.66; Cl, 19.18. 1H NMR (300 MHz, d4-MeOD) δ
7.73 (1H, s), 6.48 (1H, s), 4.37 (1H, dd, J = 11.3, 5.4 Hz), 4.28 (1H, dd, J = 11.3, 6.6 Hz),
4.06 (1H, m), 3.82 (3H, s), 3.78 (1h, m), 3.48 (1H, m), 3.29 – 3.10 (2H, m), 2.54 (1H, m),
2.38 – 1.85 (6H, m).
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C NMR (75 MHz, d4-MeOD) δ 166.3, 162.0, 151.6, 134.0, 110.4,

108.0, 98.8, 71.8, 64.9, 56.3, 55.9, 55.6, 45.3, 31.0, 30.1, 25.6.
(1R,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethyl 6-chloroimidazo[1,2-a]pyridine-8carboxylate (13b). To NaH (91 mg of 60%, 2.30 mmol, washed with hexane) was added
a solution of alcohol 9 (162 mg, 1.15 mmol) in DMF (2 mL) at 0°C. After 0.5 h the
solution of this sodium salt was added to the imidazolide of imidazopyridine carboxylic
acid [prepared by adding added CDI (186 mg, 1.15 mmol) to a solution of 6chloroimidazo[1,2-a]pyridine-8-carboxylic acid 19 (267 mg, 1.15 mmol) in DMF (2 mL)
at 0°C.] After 0.5 h at 0°C the solution was allowed to warm to rt over 3 h.
Concentration gave a residue that was quenched with water (20 mL) and extracted with
CHCl3 (3X). The combined organic extracts were washed with water (2X) and brine and
dried over Na2SO4. Concentration gave a pale yellow oil (210 mg) which was purified by
recrystallization from EA to afford the desired pyrrolizidine ester free base (155 mg,
42%) as yellow crystals: mp 116-117°C. IR (MIR) 3100, 1690, 1537, 1494, 1307, 1277
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cm-1; 1H NMR (300 MHz, CDCl3) δ 8.65 (1H, d, J = 1.8 Hz), 7.88 (1h, d, J = 1.8 Hz),
7.80 (1H, s), 7.65 (1H, s), 4.46 (2H, m), 3.36 (1H, q, J = 6.5 Hz), 3.23 (1H, t, J = 7.6 Hz)
3.00 (1h, dt, J = 10.2, 5.9 Hz), 2.60 (2H, m), 2.21 (1H, m), 2.14 (1H, m), 1.98 (1H, m),
1.90 – 1.73 (3H, m), 1.62 (1H, m). To a solution of this free base (89.1 mg, 0.28 mmol)
was added HCl/MeOH [prepared by the addition of acetyl chloride (17.8 uL, 19.6 mg,
0.279 mmol) to MeOH (1.5 mL)]. After 1 h at rt the solution was concentrated and the
resulting solid was triturated with EA and then dried to afford the requisite
imidazopyridine ester 13b (92 mg, 92%) as an off-white powder: mp 192°C (dec); IR
(MIR) 3400, 3093, 2969, 2479, 1721, 1543, 1304, 1282, 1187 cm-1. 1H NMR (300 MHz,
d4-MeOD) δ 8.99 (1H, d, J = 1.8 Hz), 8.14 (1H, d, J = 1.4 Hz), 8.07 (1H, d, J = 1.1 Hz),
7.83 (1H, s), 4.57 (1H, dd, J = 11.1, 3.5 Hz), 4.48 (1H, dd, J = 11.1, 2.3 Hz), 4.29 (1H, td,
J= 8.8, 0.8 Hz), 3.84 (2H, AB m), 3.55 (1H, m), 3.22 (1H, m), 2.91 (1H, m), 2.63 (1H,
m), 2.46 – 1.87 (4H, m).

13

C NMR (75 MHz, d4-MeOD) δ 164.3, 142.1, 134.7, 133.1,

131.1, 121.2, 119.6, 116.2, 72.1, 70.7, 55.4, 55.2, 42.7, 30.3, 29.2, 24.6. HRMS calcd for
C16H18N3O2Cl 321.1040, found 321.1049. Anal calcd for C16H18N3O2Cl.HCl:0.25H2O
C, 53.27; H, 5.45; N, 11.65; Cl, 19.66. Found C, 53.06; H, 5.36; N, 11.57; Cl, 19.54.
1-Methyl-1H-indole-2-carboxylic acid-(1R,7aS)-1-(hexahydro-pyrrolizin-1-yl)methyl
ester (13c). To indole 2-carboxylic acid (186 mg, 1.06 mmol) dissolved in DMF (2.5
mL) was added 1,1’-carbonyldiimidazole (172 mg, 1.06 mmol) at ambient temperature
and stirred. After 1.5 h alcohol 3 (150 mg, 1.06 mmol) in DMF (0.5 mL) was added and
the reaction was stirred for 16 h. Solvent was evaporated to give the desired ester as an
oil. Purification on silica gel eluting with MeOH (saturated with NH3)/CHCl3 (10/90)
gave the ester (170 mg, 53%) as a solid: 1H NMR (300 MHz, CD3OD) δ 7.68 (m, 1H),
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7.37 (d, 2H), 7.35 (d, 1H), 7.16 (t, 1H), 7.10 (s, 1H), 4.64 (dd, 2H), 4.09 (m, 1H), 3.37 (q,
1H), 3.24 (t, 1H), 3.00 (m, 1H), 2.61 (m, 2H), 2.20-1.77 (m, 6H), 1.964 (septet, 1H). To
a solution of this free base (150 mg, 0.50 mmol) was added HCl/MeOH [prepared by the
addition of acetyl chloride (72 µL, 1.00 mmol) to MeOH]. After 1 h at rt the solution was
concentrated and resulting solid was triturated with diethyl ether and then dried to give
the desired hydrochloride salt 13c (140 mg, 83%). 1H NMR (300 MHz, CD3OD) δ 7.647.56 (d, 1H), 7.49 (d, 1H), 7.35 (d, 1H), 7.33 (s, 1H), 7.12 (t, 1H); 4.44 (qq, 2H), 4.10 (m,
1H), 4.05 (s, 3H), 3.82 (m, 1H), 3.49 (m, 1H), 3.26-3.18, (m, 2H); 2.62 (m, 1H), 2.36 (m,
2H), 2.21-2.29 (m, 2H), 1.98-2.02 (m, 2H). HRMS calcd for C18H22N2O2 298.1673,
found 298.1686.
(1R,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethyl 1-methyl-1H-indole-3-carboxylate
(13d). To N-methylindole-3-carboxylic acid53 ( 2.0 g, 11 mmol) in DMF (10 mL) was
added 1,1'-carbonyldiimidazole (1.78 g, 11 mmol) and the solution was stirred at rt for
3h. Water (20 mL) and ice (30 g) were added and the mixture was extracted with
chloroform (3X). The combined organic extracts were washed with brine and dried over
magnesium sulfate. Concentration gave the intermediate imidazolide (2.4 g, 93%) which
was used directly.
To a suspension of sodium hydride (312 mg of 60% NaH, 7.8 mmol; washed with
hexane) in DMF (5 mL) at 0°C was added a solution of alcohol 9 (1.1 g, 7.8 mmol) in
DMF (6 mL). The resulting mixture was stirred at 0°C for 0.5 h after which time a
solution of the imidazolide (1.76 g, 7.8 mmol) in DMF (5 mL) was added. The reaction
was allowed to warm to rt for 16 h. The mixture was then concentrated to give a solid
which was chromatographed on silica gel (50 g) eluting with MeOH (saturated with
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NH3)/CHCl3 (5/95) to give the free base of 13d (2.03 g, 87%). To a solution of this free
base (2.0 g, 6.70 mmol) in methanol (10 mL) was added methanolic HCl [prepared by the
addition of acetyl chloride (0.48 mL, 6.7 mmol) to methanol (10 mL) at 0°C].
Concentration gave a foam which was redissolved in a minimum amount of methanol and
added dropwise to diethyl ether (700 mL) with vigorous stirring. Filtration gave a beige
solid (2.02 g) which contained the desired indole carboxylate as well as imidazole
hydrochloride. This material was recrystallized from diethyl ether/ethanol to give the title
compound 13d (1.19 g, 60%) as a colorless solid: 1H NMR (400 MHz, d4-MeOD) δ 8.45
(1H, d, J= 6 Hz), 8.00 (1H, s), 7.46 (1H, d J= 6 Hz), 7.3 to 7.2 (2H, m), 4.45 to 4.34 (2H,
m), 4.14 to 4.08 (1H, m), 3.862 (3H, s), 3.83 to 3.77 (1H, m), 3.51 to 3.45 (1H, m), 3.26
to 3.13 (2H, m), 2.64 to 2.55 (1H, m), 2.38 to 2.30 (1H, m), 2.27 to 2.15 (2H, m), 2.11 to
1.93 (3H, m). Analysis calculated for C18H22N2O2.HCl: C, 64.61; H, 6.92; N, 8.37; Cl,
10.59. Found C, 64.31; H, 7.24; N, 8.65; Cl, 10.95. Purity by HPLC 99.9%.
(1R,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethyl 5-methoxy-1H-indole-3carboxylate hydrochloride (13e). To 5-methoxyindole-3-carboxylic acid (203 mg, 1.06
mmol) dissolved in DMF (2.5 mL) was added 1,1’-carbodiimidazole (172 mg, 1.06
mmol) at ambient temperature. After 1.5 hours alcohol 9 (150 mg, 1.06 mmol) in DMF
(0.5 mL) was added and the reaction was stirred for 16 h. The solvent was concentrated
to afford an oil. Purification on silica gel (20 g) eluting with MeOH (saturated with
NH3)/CHCl3 (10/90) gave the ester as a solid (120 mg, 36%). To a solution of this free
base (110 mg, 0.35 mmol) was added HCl/MeOH [prepared by the addition of acetyl
chloride (50 µl, 0.70 mmol) to MeOH]. After 1 h at rt the solution was concentrated and
resulting solid was triturated with diethyl ether and then dried to give the desired
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hydrochloride salt 13e (56 mg, 46%). 1H NMR (300 MHz, CD3OD) δ 7.95 (s, 1H), 7.54
(d, 1H), 7.32 (d, 1H), 6.87 (dd, 1H), 4.41 (m, 2H), 4.09 (m, 1H), 3.84 (s, 3H), 3.79 (m,
1H), 3.49 (m, 1H), 3.19 (m, 2H), 2.61 (m, 1H), 2.36 (m, 2H), 2.21 (m, 2H), 2.03 (m, 2H).
Anal calcd C18H22N2O3:HCl:0.33H2O: C, 60.59; H, 6.68; N, 7.85; Cl, 9.94. Found: C,
60.78; H, 6.54; N, 7.81; Cl, 9.69.
(1R,7aS)-Hexahydro-1H-pyrrolizin-1-ylmethyl 5-fluoro-1H-indole-3-carboxylate
hydrochloride (13f). To 5-fluoroindole-3-carboxylic acid (190 mg, 1.06 mmol)
dissolved in DMF (2.5 mL) was added 1,1’-carbodiimidazole (172 mg, 1.06 mmol) at
ambient temperature. After 1.5 h alcohol 9 (150 mg, 1.06 mmol) in DMF (0.5 mL) was
added and stirred for 16 hours. Solvent was concentrated to give desired ester as an oil.
Purification on silica gel (20 g) eluting with MeOH (saturated with NH3)/CHCl3 (10/90)
gave the ester as a solid (170 mg, 53%). To a solution of this free base (160 mg, 0.53
mmol) was added HCl/MeOH [prepared by the addition of acetyl chloride (75 µl, 1.06
mmol) to MeOH]. After 1 h at rt the solution was concentrated and resulting solid was
triturated with diethyl ether and then dried to give the desired hydrochloride salt 13f (133
mg, 74%). Anal calcd C17H19N2O2F:HCl:0.33 H2O: C, 59.32; H, 6.03; N, 8.14; Cl,
10.36. Found C, 59.58; H, 6.13; N, 8.20; Cl, 10.36. 1H NMR (300 MHz, CD3OD) δ
8.05 (s, 1H), 7.69 (dd, 1H), 7.42 (dd, 1H), 6.99 (t, 1H), 4.42 (m, 2H), 4.09 (m, 1H), 3.80
(m, 1H), 3.49 (m, 1H), 3.19 (m, 2H), 2.62 (m, 1H), 2.36 (m, 2H), 2.22 (m, 2H), 2.02 (m,
2H).
(1S,7aR)-Hexahydro-1H-pyrrolizin-1-ylmethyl 1H-indazole-3-carboxylate (13g).
To indazole-3-carboxylic acid (172 mg, 1.06 mmol) dissolved in DMF (3 mL) was added
1,1’-carbodiimidazole (172 mg, 1.06 mmol) at rt and stirred for 1.5 h after which time
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alcohol 9 (150 mg, 1.06 mmol) in DMF (0.5 mL) was added and the reaction was stirred
for 16 h. Solvent was concentrated to give desired ester as an oil. Purification on silica
gel eluting with MeOH (saturated with NH3)/CHCl3 (5/95) gave the ester as a solid (205
mg, 68%). 1H NMR (300 MHz, CDCl3) δ 13.08 (s, 1H), 8.14 (d, 1H), 7.62 (d, 1H), 7.36
(t, 1H), 7.22 (t, 1H), 4.49 (m, 2H), 3.54 (q, 1H), 3.39 (m, 1H), 3.11 (quintet, 1H), 2.68
(m, 1H), 2.29 (m, 1H), 2.15 (m, 1H), 2.02 (septet, 1H), 1.85 (m, 4H), 1.67 (s, 1H).
HRMS calcd for C16H19N3O2 285.1474, Found: 285.1500. Anal calcd for
C16H19N3O2:0.5H2O C, 65.29; H, 6.85; N, 14.28. Found: C, 65.39; H, 6.56; N, 14.01. To
a solution of this free base (160 mg, 0.56 mmol) was added HCl/MeOH [prepared by the
addition of acetyl chloride (80 µL, 1.12 mmol) to MeOH]. After 1 h of stirring at rt the
solution was concentrated and resulting solid was triturated with diethyl ether and then
dried to give the desired hydrochloride salt 13g (137 mg, 76%): 1H NMR (400 MHz, d4MeOD) δ 8.14 (1H, d, J=8.2 Hz), 6.62 (1H, d, 8.5 Hz), 7.46 (1H, t, J= 8 Hz), 7.32 (1H, t,
J= 8 Hz), 4.59 to 4.49 (2H, m), 4.16 (1H, t, J= 6 Hz), 3.87 to 3.82 (1H, m), 3.54 to 3.48
(2H, m), 3.27 to 3.17 (1H, m), 2.73 to 2.64 (1H, m), 2.43 to 2.36 (1H, m), 2.32 to 2.17
(2H, m), 2.10 to 1.98 (3H, m). HRMS calcd for C16H19N3O2: 285.1496, found: 285.1511.
Anal calcd for C16H19N3O2:HCl:0.15H2O: C, 59.22; H, 6.31; N, 12.95, Cl, 10.93. Found
C, 59.13; H, 6.34; N, 12.88, Cl, 11.06.
(1S,7aR)-Hexahydro-1H-pyrrolizin-1-ylmethyl 1-methyl-1H-indazole-3carboxylate (13h). To N-methylindazole-3-carboxylic acid (186 mg, 1.06 mmol)
dissolved in DMF (2 mL) was added 1,1’-carbodiimidazole (172 mg, 1.06 mmol) at
ambient temperature. After stirring for 1.5 h the alcohol 9 (150 mg, 1.06 mmol) in DMF
(0.5 mL) was added and the reaction stirred for 16 hours. Solvent was removed in vacuo
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to give an oil. Purification on silica gel eluting with MeOH (saturated with NH3)/CHCl3
(10/90) gave the ester as a solid (196 mg, 62%). 1H NMR (300 MHz, CDCl3) δ 8.20 (d,
1H), 7.47 (d, 2H), 7.34 (t, 1H), 4.49 (m, 2H), 4.18 (S, 3H), 3.37 (q, 1H), 3.21 (m, 1H),
2.99 (m, 1H), 2.59 (m, 2H), 2.37 (m, 1H), 2.16 (m, 1H), 2.16 (m, 1H), 1.99 (septet, 1H),
1.81 (m, 2H), 1.61 (sextet, 1H). HRMS calcd for C17H21N3O2: 299.1616, found
285.1632. Anal calcd for C17H21N3O2:0.2H2O: C, 67.39; H, 7.12; N, 13.87. Found C,
67.54; H, 6.99; N, 13.74. To a solution of this free base (168 mg, 0.56 mmol) was added
HCl/MeOH [prepared by the addition of acetyl chloride (80 µL, 1.12 mmol) to MeOH].
After 1 h at rt the solution was concentrated and resulting solid was triturated with diethyl
ether and then dried to give the desired hydrochloride salt 13h (174 mg, 92%). Anal
calcd C17H21N3O2:HCl:0.15 H2O: C, 60.31; H, 6.64; N, 12.41; Cl, 10.47. Found: C,
60.28; H, 6.76; N, 12.40; Cl, 10.71. HRMS calcd C17H21N3O2: 299.1649, found:
299.1648. 1H NMR (400 MHz, CDCl3) δ 8.12 (d, 1H), 7.69 (d, 1H), 7.51 (t, 1H), 4.52
(qq, 2H), 4.16 (S, 3H), 4.13 (m, 1H), 3.84 (m, 1H), 3.50 (m, 1H), 3.22 (m, 2H), 2.69 (m,
1H), 2.40 (m, 1H), 2.22 (m, 5H), 2.05 (m, 1H).
cis-N-[(Hexahydro-1H-pyrrolizin-l-yl)methyl]-2,3- dihydro-3-(1-methylethyl)-2oxo-lH-benzimidazole-l-carboxamide (15a). A dispersion of 60% NaH/mineral oil (80
mg, 0.002 mol) was washed with hexane and suspended in THF. Solid 1,3-dihydro-l-(lmethylethyl)-2H-benzimidazol-2-one54 (176 mg, 1.00 mmol) was added to the
suspension. This mixture was stirred 15 minutes before adding to a solution of 2.5 mL
(0.004 mol) of 20% phosgene in toluene/2.5 mL THF. The resulting mixture was filtered
through celite and concentrated. The residue was dissolved in THF (5.0 mL) and a
solution of aminomethylpyrrolizidine 11 (140 mg, 1.0 mmol) was added in Et3N (0.5
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mL). This mixture was stirred for 1 h, filtered and concentrated. The residue was purified
by preparative thin-layer chromatography eluting with 30/70 MeOH/CHCl3 containing
0.25% NH4OH. The product was rinsed from the silica with 9/95 NH4OH/MeOH. The
filtrate was concentrated and the residue was dissolved in CHCl3 and filtered through
celite and concentrated to afford the benzimidazolone 15a (157 mg, 50%). The product
was converted to the HCl salt by dissolving 36 uL of acetyl chloride in 5.0 mL of MeOH
and adding this solution to the product, then concentrating to dryness: 1H NMR (400
MHz, d4-MeOD) δ 8.11 (1H, dd, J= 8.1, 0.8 Hz), 7.32 (1H, dd, J= 8.1, 0.8 Hz), 7.22 (1H,
d of t, J= 8.1, J= 1 Hz), 7.13 (1H, d of t, J= 8.1, J= 1 Hz), 4.70 (1H, sep, J= 7 Hz), 4.04 to
3.96 (1H, m), 3.82 to 3.74 (1H, m), 3.58 to 3.55 (2H, m), 3.50 to 3.42 (1H, m), 3.25 to
3.18 (1H, m), 3.16 to 3.08 (1H, m), 2.49 to 2.39 (1H, m), 2.36 to 2.26 (1H, m), 2.25 to
2.17 (1H, m), 2.11 to 2.03 (1H, m), 2.01 to 1.93 (1H, m), 1.91 to1.82 (1H, m), 1.54 (2H,
d, J= 7 Hz). MS MH+ calcd for C19H26N4O2 343, found 343. Anal calcd for
C19H26N4O2.HCl.H2O C, 57.50; H, 7.32; N, 14.12; Cl, 8.93. Found C, 57.44; H, 7.42; N,
13.87; Cl, 8.93.
exo-2,3-Dihydro-3,3-dimethyl-N-[(hexahydro-lH-pyrrolizin- 1S-yl)methyl]-2-oxo1H-indole-1-carboxamide, hydrate hydrochloride (15b). To sodium hydride (214 mg,
5.6 mmol, washed 2X with hexane) suspended in THF (1 mL) was added 1,3-dihydro3,3-dimethyl-2H-indol-2-one55 (226 mg, 1.4 mmol) and the reaction was stirred for 10
minutes. The resulting suspension was added to a solution of 20% phosgene in toluene
(5.50 mL, 11.2 mmol) in THF (5 mL) and the reaction was stirred for 1 hour. The
reaction mixture was filtered through celite and concentrated in vacuo to give an oil. To a
solution of the oil in THF (5 mL) was added a solution of aminomethylpyrrolizidine 11
(200 mg, 1.4 mmol) and triethylamine (200 uL, 1.4 mmol) in THF (2 mL) and the
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reaction was stirred for 18 hours. The solution was then diluted with chloroform, washed
with saturated K2CO3 solution, dried over K2CO3, filtered and concentrated in vacuo to
give crude desired product as an oil. Purification on silica gel eluting with 10%
CH3OH(NH3)/CHCl3 gave the free base of the benzimidazolone (193 mg, 42%) as a
solid: Analysis calculated for C19H25N302:0.4H20 C, 68.19; H, 7.77; N, 12.56. Found C,
68.06; H, 7.74; N, 12.44. HRMS calculated for C19H25N302: 327.1947, found 327.1930.
The free base (180 mg, 0.550 mmol) was converted to the hydrochloride salt by treatment
with methanolic HCl to give the hydrochloride salt 15b (128 mg, 64%) as a solid: 1H
NMR (400 MHz, d4-MeOD) δ 8.10 (1H, d, J= 2 Hz), 7.33 (1H, d, J= 2Hz), 7.28 (1H, t, J=
2 Hz), 7.19 (1H, t, J= 2 Hz), 4.02 to 3.96 (1H, m), 3.79 to 3.74 (1H, m), 3.53 (2H, d, J=
6.4 Hz), 3.49 to 3.43 (1H, m), 3.24 to 3.18 (1H, m), 3.15 to3.08 (1H, m), 2.48 to 2.38
(1H, m), 2.33 to 2.25 (1H, m), 2.22 to 2.13 (2H, m), 2.08 to 1.02 (1H, m), 1.99 to 1.92
(1H, m), 1.90 to 1.83 (1H, m), 1.41 (6H, s). Analysis calculated for
C19H25N302.HCl:0.25H20 C, 61.95; H, 6.98; N, 11.41; Cl, 9.62. Found C, 61.54; H, 6.92;
N, 11.36; Cl, 9.90. MS calculated for C19H25N302: 327.1947, found: 327.1939.
Imidazol[1,2-a]pyridine-8-carboxylic acid monohydrochloride (17). 2Aminonicotinic acid 16 (14.1 g; 0.102 mol) and chloroacetaldehyde [45% aqueous
solution] (8.6 g, 100 mmol) were dissolved in EtOH (100 mL) and heated to reflux. The
reaction was monitored by tlc with 30% MeOH/CH2Cl2/1.0% HOAc, and additional
chloroacetaldehyde was added until the starting material was consumed. The reaction
mixture was concentrated and the solid filtered and washed with EtOH and suction dried
to yield imidazol[1,2-a]pyridine-8-carboxylic acid monohydrochloride 17 (17.5 g, 88%)
as a solid: IR: 1582, 1651, 1687, 3049 and 3320 cm-1. Anal calcd for C8H6N2O2.HCl
48.38; H: 3.55; N: 14.10; Cl: 17.85. Found: C: 48.16; H: 3.59; N: 13.95; Cl: 17.50.
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6-Chloroimidazo[1,2-a]pyridine-8-carboxylic acid (19). Methyl 2-amino-5chloronicotinate 18 (7.0 g; 0.045 mol) and 45% aqueous chloroacetaldehyde (10.5 g; 0.06
mol) were dissolved in EtOH (100 mL) and heated to reflux for 3 h. The reaction mixture
was concentrated and the solid filtered and washed with EtOH and suction dried to yield
methyl 6-chloroimidazo[1,2-a]pyridine-8-carboxylate (9.5 g, 80%) as a solid. Anal calcd
for C9H7N2O2.HCl.H2O C: 40.78; H: 3.80; N: 10.57; Cl: 26.75. Found: C: 40.68; H:
3.74; N: 10.19; Cl: 26.85.
The methyl 6-chloroimidazo[1,2-a]pyridine-8-carboxylate (9.5 g, 0.036 mol) was
combined with 6N HCl (100 mL) and heated to reflux for 2 h. The reaction mixture was
concentrated to near dryness. The residue was suspended in acetone and the solid filtered
and washed with acetone to yield 6-chloroimidazo[1,2-a]pyridine-8-carboxylic acid 19
hydrochloride salt (6.3 g, 75.5%) as a solid: IR: 1679 and 3281 cm-1. Anal calcd for
C8H5N2O2.HCl C: 41.23; H: 2.60; N: 12.02; Cl: 30.42. Found: C: 40.95; H: 2.43; N:
12.16; Cl: 30.67.
(+)-4-Amino-5-chloro-N-(hexahydro-2,5β
β -methano-1H-3aS,3aα
α,6aα
αcyclopenta[c]pyrrol-4α
α-yl)-2-methoxybenzamide, monohydrochloride (6, SC-52491).
Compound 6 was prepared initially by synthesis involving resolution as previously
described41 then via an enantioselective synthesis commencing with an asymmetric DielsAlder reaction.52

Serotonin 5-HT3 Receptor Binding
Displacement of [3H]-GR65630 from brain cortex obtained from male Wistar rats was
done by the method of Kilpatrick.56 Cortical membrane preparations (0.04 mg) were
incubated with 0.2 nM [3H]-GR65630 in the presence or absence of graded
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concentrations test compound for 60 min at 22°C. One micromolar of tropisetron was
used for nonspecific binding to the membranes. Membranes were filtered, washed three
times and counted to obtain binding displacement curves and determine specific binding
of [3H]-GR65630 to the 5-HT3 receptor.

Serotonin 5-HT4 Receptor Binding
Serotonin 5-HT4 receptor binding in guinea pig striatum utilizing [3H]-GR113,808 was
performed by MDS Pharma Services [formerly Panlabs Taiwan] according to the method
of Grossman and Kilpatrick.57

Selectivity Binding Assays
The following radioligands were used for receptor profiling studies: [3H]-5HT for 5HT1-like receptors; [3H]-ketanserin for 5-HT2 receptors; [3H]-SCH23390 for D1
receptors; [3H]-spiperone for D2 receptors; and [3H]-prazosin for α1-adrenergic receptors.

In Vitro Functional Assay for Serotonin 5-HT4 agonism in the Rat TMM (tunica
muscularis mucosae) Assay
Serotonin 5-HT4 agonism was measured in the rat esophagus in vitro preparation as
reported by Baxter.2,57 Agonist activity was determined utilizing relaxation of carbacholcontracted rat tunica muscularis mucosae. One 2 cm segment of intrathoracic esophagus
proximal to the diaphragm was removed from male rats weighing approximately 300 g,
and the outer muscle layers removed. The inner tunica muscularis mucosa was mounted
under 0.2-0.3 g of tension in a tissue bath containing oxygenated Tyrode's solution at
37°C. Cortisterone acetate (30 µM) and fluoxetine (1 µM) were included in the buffer to
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prevent uptake of serotonin, as well as pargyline (10 µM) to inhibit monoamine oxidase.
Following a 30 min equilibrium period, tissues were isometrically contracted with
carbachol (3 µM) to obtain a tonic contraction. A stable plateau was obtained within 20
min when test compound was added cumulatively to relax the muscle strip. EC50 values
were obtained for each agonist in tissues from rats.

5-HT4 Receptor Antagonism in the Rat TMM (tunica muscularis mucosae) Assay
Antagonist activity of compounds at 5-HT4 receptors was determined in a manner
similar to the in vitro agonism activity described by Gullikson.39 Cumulative doseresponse curves for agonists interacting with 5-HT4 receptors of rat TMM were done
according to the method of Baxter.2 Male Sprague-Dawley rats (300 - 400 g) from
Charles River Laboratories (Wilmington, MA) were asphyxiated with CO2 and the TMM
were isolated from 2 cm segments of rat esophagus obtained orad to the diaphragm. the
TMM was mounted in a 37°C tissue bath under 2 to 3 mN of tension for 60 min before
the study. The tissues were suspended in and washed with continuously oxygenated (95%
O2/5% CO2) Tyrode's buffer which contained fluoxetine (1 µM) and corticosterone (30
µM) to prevent tissue uptake of 5-HT, methysergide (1 µM) to block 5-HT1 and 5-HT2
receptors, and pargyline (100 µM) to prevent oxidation of 5-HT by monoamine oxidase.
Selected concentrations of antagonist were added to the tissue bath 5 min after TMM
were contracted with 3 µM of carbachol. Relaxant responses to cumulative additions of 5HT or 5-HT4 agonists (from 10-10 to 10-5 M in half-log increments at 2.5-min intervals)
were started 20 min after addition of the carbachol. Agonist ability to relax TMM was
expressed relative to the maximum relaxant response by the agonist in the absence of
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antagonist. EC50 values were calculated as the concentrations causing 50% of this
maximal effect. EC50 ratios (dose ratios) from the agonist concentration-response curves
in the absence and presence of three increasing concentrations of antagonist for each
tissue were calculated. Dose ratios from at least four tissues for each of the three
antagonist concentrations were used for Schild plot analysis to determine the mean pA,
value ± S.E.M. of the antagonist.58 The pA2 value for single antagonist concentrations in
individual tissues was also calculated using the method of MacKay: pA2 = -log
(antagonist concentration [mol/1]) + log (DR-1). A mean pA2 value ± S.E.M. was
calculated from the individual pA2 values from at least four tissues for a single
concentration of the antagonist.

von Bezold-Jarisch Reflex Assay
According to the method of Saxena and Lawang,40 the test sample was administered i.p.
(mg/kg) to a group of 3 mice. Thirty minutes later, a 5-HT (0.25 mg/kg i.v.)-induced
bradycardia was recorded in pentobarbital anesthetized animals. A greater than 50 percent
(>50) reduction in the bradycardic response relative to vehicle-treated control mice is
considered significant.

Antral Motility in Conscious Fasted Dogs
Gastric antral contractile activity is stimulated by prokinetic drugs which enhance
gastric emptying of solid food.59 This contractile activity is thought to enhance gastric
emptying by more rapidly reducing food particle size for passage through the pylorus.
The ability of the test compound to increase the frequency and/or amplitude of the
contractile activity is therefore a measure of GI prokinetic activity of compounds.
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Mongrel dogs of either sex weighing 15-25 kg were surgically implanted with strain
gauge force transducers on the gastric antrum at 6 cm, 4 cm and 2 cm from the
gastroduodenal junction. Strain gauge transducers were also implanted on the ileum and
proximal colon. Silver monopolar electrodes were implanted on the jejunum. The dogs
were allowed at least two weeks to recover and were trained to stand quietly in Pavlov
slings. Dogs were fasted for 18-24 hours prior to each experiment to record a pattern of
antral contractile activity characteristic of the fasted state called the migrating motor
complex (MMC). The period of the MMC cycle is approximately 90-120 minutes and
consists of 45-60 minutes of motor quiescence (Phase I) 30-45 minutes of intermittent
activity (Phase II) and 10-15 minutes of intense contractile activity (Phase III). A control
MMC period is recorded prior to compound administration to obtain the length of the
quiescent Phase I period. Compound is given intravenously at the end of Phase III of the
control MMC cycle and the subsequent Phase I period is examined for the ability of the
compound to produce contractions. A compound is considered active if it produces any
contractile activity during the normally quiescent Phase I. A motility index of cumulative
activity consisting of frequency and amplitude components, is used to quantitatively
describe the total contractile activity of a time period after compound administration
equal to the control MMC period.

Canine Gastric Emptying In Vivo Model
Determination of the effects of test compounds on gastric emptying of solid meals in
nonsedated dogs was done in separate experiments in an α2-adrenergic model of
gastroparesis as described by Gullikson.45,60 Dogs weighing 15-25 kg were trained to
stand quietly in Pavlov slings for 3-4 hours, and consistent control emptying responses
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were obtained prior to use in gastric emptying experiments with the test compounds. The
solid meal consisted of 2 cooked scrambled eggs which were divided into 1 cm sized
pieces and mixed with beef stew. One mCi of Tc-99m sulfur colloid was incorporated
into the eggs prior to cooking. The dogs were fasted for at least 24 hours prior to the
study and were fed the solid meal by intragastric tube. To delay normal gastric emptying
0.030 mg/kg of α2-adrenergic agonist 2-methyl-3-[(2E)-pyrrolidin-2-ylideneamino]phenol
was administered immediately following the meal. The test compounds were given via
intravenous injection 45 minutes prior to feeding.
A Siemens 370 ZLC gamma camera with high resolution low energy collimator was
used to acquire left lateral images during emptying studies. Acquisition times were 3
min/frame for 180 min solid emptying. Disappearance of contents from the stomach
region of interest was plotted over time to obtain emptying curves. The amount of solid
meal remaining in the stomach at the end of each experiment and the fractional solid
emptying rate (% emptied per min) were calculated from linear regression equations
describing solid emptying. Emptying measurements obtained from one replicate of each
drug treatment were compared to the means of at least 3 control responses for the α2adrenergic agonist in solid emptying studies.

Ames Mutagenicity Assay
Pyrrolizidine benzamide 12a was tested for mutagenic activity in a GLP study using the
Ames Salmonella/microsome assay with five strains of Salmonella typhimurium
(TA1535, TA100, TA1538, TA97, and TA98) in the presence and absence of a rat liver
homogenate metabolic activation system (S9) over test article concentrations ranging
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from 7.2 to 3600 µg/plate. Significant test article-related increases of 4X in the number
of revertant colonies were observed in strain TA98 with activation at 3600 µg/plate. A 23X increase was observed with activation in strain TA100 between 710 ug and 3600
µg/plate, and a 2-6X increase was observed with activation in strain TA1538 also
between 720 µg and 3600 µg/plate. Significant increases in numbers of revertant
colonies were not observed in the test without S9 activation.
Pyrrolizidine benzamide ent-12a was tested for mutagenic activity in a GLP study
using the Ames Salmonella/microsome assay with five strains of Salmonella
typhimurium (TA1535, TA100, TA1538, TA97, and TA98) in the presence and absence
of a rat liver homogenate metabolic activation system (S9) over test article concentrations
ranging from 10 to 5000 µg/plate. There were no test article-related increases in the
number of revertant colonies or cytotoxic effects observed in any of the tester strains with
or without activation. These data support the conclusion that ent-12a is not mutagenic
under the conditions of this test system.
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Figure 1. 5-HT4 Agonists and Antagonists
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Scheme 5. Preparation of imidazol[1,2-a]pyridine-8-carboxylic acid 17 and 6chloroimidazo[1,2-a]pyridine-8-carboxylic acid 19
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Scheme 6. Preparation of 6-chloroimidazo[1,2-a]pyridine-3-methyl-8-carboxylic acid 21
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Figure 2. 5-HT4 receptor-mediated relaxation of rat tunica muscularis mucosa by 5-HT,
12a (SC-53116) and ent-12a (SC-53117).
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Figure 3. Gastrointestinal response to compound 12a (0.3 mpk, iv) in the dog.
Contractile responses of the antrum (panel 1), jejunum (panel 2), ileum (panel 3) and
colon (panel 4) before and after 5-HT4 partial agonist 12a is given iv to fasted dogs (n=4).
A sustained stimulation of antral and jejunal motility occurs with brief augmentation of
ileal and colonic contractions.
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Figure 4. Stimulation of gastric antral contractions by 12a (SC-53116), ent-12a (SC53117) and 1 (cisapride) given in Phase 1 of the MMC cycle as the percentage of
maximal activity seen during Phase 3 of the MMC.
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Figure 5. Enhancement of gastric emptying of radio-labeled solid meals by 12a (SC53116), ent-12a, (SC-53117) and 1 (cisapride).
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Table 2. Pyrrolizidine amide and urea 5-HT4 antagonists
R

H
12d-i, 15b

N
Entry

R

5-HT4
Antagonism
pA2 in rat
TMM
IA at 10-7 M

O

12d

N
H
N
CH3
O

12e

IA @ 10-6 M
N
H

N
Et
O

12f

N
H

N

N

6.56

Et
O

12g

6.75 (0.05)
N
H

N

N
O

12h
Cl

N
H
N

N
O

12i
Cl

7.09 (0.08)
N
H

N

15b

8.13 (0.06)

N

O

H
N

7.0

N
O
H3C

CH3
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Table 3. Pyrrolizidine ester 5-HT4 antagonists
R

H
13b-h

N
Entry

R

5-HT4 Binding,
(Ki, nM)

O

13b
Cl

…

5-HT4
Antagonism:
pA2 in rat
TMM
6.75

…

5-HT1, 5-HT2,
D1, D2, α1, α2,
β1, β2 binding
Ki, nM
…

…

IA at 10-7 M

…

…

0.183 (0.017)

8.93(0.07)

5.0 (1.0)

>10K

…

7.15

…

…

0.70 (0.15)

8.50

10 (1)

…

0.80 (0.83)

8.48

135 (5)

>10K

0.40 (0.033)

8.56

20 (2)

>10K

5-HT3
binding Ki,
nM (SEM)

O
N

N

13c
O

N
CH3 O
O

13d

O
N
CH3
O

13e
MeO

O
N
H

O

13f
F

O
N
H
O

13g

O
N
H

N

O

13h

O
N

N
CH3
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Table 4. Comparison of enantiomers 12a and ent-12a with 1 and 2.
Assay
5-HT4 Agonism Rat TMM
(EC50, nM)
Antral Contractility in Fasted
Dog (ED50, mpk, iv)
Solid Gastric Emptying
(ED50, mpk, iv)

1
55±8

2
98±14

12a
17 ±4

ent-12a
323±46

0.048

0.015

0.010

0.45

0.03

Active, but full
dose-response not
performed

0.001

1.0
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Table 5. Receptor profiling of compounds: EC50, nM [5-HT4 agonism] or Ki, nM [all
others]
Cmpd
1
12a
12h
6

5-HT4
agonism
54.7
16.5
>10K
51

5-HT4

5-HT1

5-HT2

5-HT3

D1

D2

α1

α2

β

17
5.2
1.4
29

>1K
>10K
>10K
>10K

6.1
>10K
>10K
>10K

134
152
259
1.2

1700
>10K
>10K
>10K

227
>10K
>10K
>10K

30
>10K
>10K
>10K

4500
>10K
>10K
>10K

>10K
>10K
>10K
>10K
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